Skip to main content

Marker Therapeutics, Inc.

جودة البيانات: 83%
MRKR
Nasdaq Manufacturing Chemicals
KWD 1.75
▲ KWD 0.29 (19.86%)
القيمة السوقية: 22.64 M
السعر
KWD 1.75
القيمة السوقية
22.64 M
نطاق اليوم
KWD 1.48 — KWD 1.75
نطاق 52 أسبوعًا
KWD 0.81 — KWD 4.07
حجم التداول
728,642
فتح KWD 1.48
متوسط 50 يوم / 200 يوم
KWD 1.48
18.10% above
متوسط 50 يوم / 200 يوم
KWD 1.32
32.58% above

Quick Summary

النقاط الرئيسية

Negative free cash flow of -12.01 M

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-84.24%
أقل من متوسط القطاع (-53.41%)
ROIC-70.52%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
N/A
Current Ratio6.50
Interest CoverageN/A

التقييم

PE (TTM)
-1.86
أقل من متوسط القطاع (-1.48)
P/B Ratio1.23
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1364 نظير)
المقياس السهم وسيط القطاع
P/E -1.9 -1.5
P/B 1.2 1.6
ROE % -84.2 -53.4
Net Margin % -41.5
Rev Growth 5Y % 1.8
D/E 0.3

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -12.16 M
ROE -84.24% ROA -66.65%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -12.01 M
ROIC -70.52% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 6.50
Interest Coverage N/A Asset Turnover N/A
Working Capital 18.39 M Tangible Book Value 18.39 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1.86 Forward P/E N/A
P/B Ratio 1.23 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -53.06%
Market Cap 22.64 M Enterprise Value 5.05 M
Per Share
EPS (Diluted TTM) -0.79 Revenue / Share N/A
FCF / Share -0.93 OCF / Share -0.93
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 98.77%
SBC-Adj. FCF -12.49 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0.0
Net Income -12.16 M -10.73 M -8.24 M -29.93 M -41.88 M
EPS (Diluted) -0.79 -1.19 -0.94 -3.58 -0.55
Gross Profit
Operating Income -12.89 M -11.12 M -14.58 M -29.95 M -39.48 M
EBITDA
R&D Expenses 11.80 M 13.47 M 10.42 M 26.14 M 27.79 M
SG&A Expenses
D&A 2.79 M 2.15 M
Interest Expense
Income Tax -15,156.0 49,953.0 3,675.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 19.07 M 22.02 M 17.13 M 34.42 M 68.14 M
Total Liabilities 2.27 M 3.46 M 3.07 M 14.82 M 24.15 M
Shareholders' Equity 16.80 M 18.56 M 14.05 M 19.60 M 43.99 M
Total Debt
Cash & Equivalents 16.07 M 19.19 M 15.11 M 11.78 M 42.35 M
Current Assets 19.07 M 22.02 M 17.13 M 16.62 M 45.98 M
Current Liabilities 2.27 M 3.46 M 3.07 M 7.78 M 12.90 M